RNAi for Therapeutic Market Report

Japan RNAi for Therapeutic Market Professional Research Report 2014-2026, Segmented by Players, Types, End-Users in Major Region

  • POSTDATE：Jun 19, 2020
  • PAGES：135
  • REPORT CODE：GMM561326
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report offers an overview of the market trends, drivers, and barriers with respect to the Japan RNAi for Therapeutic market. It also provides a detailed overview of the market of different regions across Hokkaido, Tohoku, Kanto, Chubu, Kinki, Chugoku, Shikoku, Kyushu. The report deep analyzes type and application in Japan RNAi for Therapeutic market. Detailed analysis of key players, along with key growth strategies adopted by RNAi for Therapeutic industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • miRagen Therapeutics

    • Sirnaomics

    • Quark Pharmaceuticals

    • Mirna Therapeutics

    • Dicerna Pharmaceuticals

    • Alnylam Pharmaceuticals

    • RXi Pharmaceuticals

    • Arrowhead

    • Gradalis

    By Type:

    • siRNA

    • miRNA

    • shRNA

    By End-User:

    • Cancer

    • Cardiovascular

    • HBV

    • Others

    By Region:

    • Hokkaido

    • Tohoku

    • Kanto

    • Chubu

    • Kinki

    • Chugoku

    • Shikoku

    • Kyushu

  • 1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of RNAi for Therapeutic Market

    • 1.3 Market Segment by Type

      • 1.3.1 Japan RNAi for Therapeutic Market Size and Growth Rate of siRNA from 2014 to 2026

      • 1.3.2 Japan RNAi for Therapeutic Market Size and Growth Rate of miRNA from 2014 to 2026

      • 1.3.3 Japan RNAi for Therapeutic Market Size and Growth Rate of shRNA from 2014 to 2026

    • 1.4 Market Segment by Application

      • 1.4.1 Market Size and Growth Rate of Cancer

      • 1.4.2 Market Size and Growth Rate of Cardiovascular

      • 1.4.3 Market Size and Growth Rate of HBV

      • 1.4.4 Market Size and Growth Rate of Others

    • 1.5 Market Segment by Regions

      • 1.5.1 Hokkaido RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 Tohoku RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 Kanto RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Chubu RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Kinki RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Chugoku RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Shikoku RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Kyushu RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of RNAi for Therapeutic Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of RNAi for Therapeutic by Major Types

      • 3.4.1 Japan RNAi for Therapeutic Market Size and Growth Rate of siRNA from 2014 to 2026

      • 3.4.2 Japan RNAi for Therapeutic Market Size and Growth Rate of miRNA from 2014 to 2026

      • 3.4.3 Japan RNAi for Therapeutic Market Size and Growth Rate of shRNA from 2014 to 2026

    4 Segmentation of RNAi for Therapeutic Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of RNAi for Therapeutic by Major End-Users

      • 4.4.1 Market Size and Growth Rate of RNAi for Therapeutic in Cancer

      • 4.4.2 Market Size and Growth Rate of RNAi for Therapeutic in Cardiovascular

      • 4.4.3 Market Size and Growth Rate of RNAi for Therapeutic in HBV

      • 4.4.4 Market Size and Growth Rate of RNAi for Therapeutic in Others

    5 Market Analysis by Regions

    • 5.1 Japan RNAi for Therapeutic Production Analysis by Regions

    • 5.2 Japan RNAi for Therapeutic Consumption Analysis by Regions

    6 Hokkaido RNAi for Therapeutic Landscape Analysis

    • 6.1 Hokkaido RNAi for Therapeutic Landscape Analysis by Major Types

    • 6.2 Hokkaido RNAi for Therapeutic Landscape Analysis by Major End-Users

    7 Tohoku RNAi for Therapeutic Landscape Analysis

    • 7.1 Tohoku RNAi for Therapeutic Landscape Analysis by Major Types

    • 7.2 Tohoku RNAi for Therapeutic Landscape Analysis by Major End-Users

    8 Kanto RNAi for Therapeutic Landscape Analysis

    • 8.1 Kanto RNAi for Therapeutic Landscape Analysis by Major Types

    • 8.2 Kanto RNAi for Therapeutic Landscape Analysis by Major End-Users

    9 Chubu RNAi for Therapeutic Landscape Analysis

    • 9.1 Chubu RNAi for Therapeutic Landscape Analysis by Major Types

    • 9.2 Chubu RNAi for Therapeutic Landscape Analysis by Major End-Users

    10 Kinki RNAi for Therapeutic Landscape Analysis

    • 10.1 Kinki RNAi for Therapeutic Landscape Analysis by Major Types

    • 10.2 Kinki RNAi for Therapeutic Landscape Analysis by Major End-Users

    11 Chugoku RNAi for Therapeutic Landscape Analysis

    • 11.1 Chugoku RNAi for Therapeutic Landscape Analysis by Major Types

    • 11.2 Chugoku RNAi for Therapeutic Landscape Analysis by Major End-Users

    12 Shikoku RNAi for Therapeutic Landscape Analysis

    • 12.1 Shikoku RNAi for Therapeutic Landscape Analysis by Major Types

    • 12.2 Shikoku RNAi for Therapeutic Landscape Analysis by Major End-Users

    13 Kyushu RNAi for Therapeutic Landscape Analysis

    • 13.1 Kyushu RNAi for Therapeutic Landscape Analysis by Major Types

    • 13.2 Kyushu RNAi for Therapeutic Landscape Analysis by Major End-Users

    14 Major Players Profiles

    • 14.1 miRagen Therapeutics

      • 14.1.1 miRagen Therapeutics Company Profile and Recent Development

      • 14.1.2 miRagen Therapeutics Market Performance

      • 14.1.3 miRagen Therapeutics Product and Service Introduction

    • 14.2 Sirnaomics

      • 14.2.1 Sirnaomics Company Profile and Recent Development

      • 14.2.2 Sirnaomics Market Performance

      • 14.2.3 Sirnaomics Product and Service Introduction

    • 14.3 Quark Pharmaceuticals

      • 14.3.1 Quark Pharmaceuticals Company Profile and Recent Development

      • 14.3.2 Quark Pharmaceuticals Market Performance

      • 14.3.3 Quark Pharmaceuticals Product and Service Introduction

    • 14.4 Mirna Therapeutics

      • 14.4.1 Mirna Therapeutics Company Profile and Recent Development

      • 14.4.2 Mirna Therapeutics Market Performance

      • 14.4.3 Mirna Therapeutics Product and Service Introduction

    • 14.5 Dicerna Pharmaceuticals

      • 14.5.1 Dicerna Pharmaceuticals Company Profile and Recent Development

      • 14.5.2 Dicerna Pharmaceuticals Market Performance

      • 14.5.3 Dicerna Pharmaceuticals Product and Service Introduction

    • 14.6 Alnylam Pharmaceuticals

      • 14.6.1 Alnylam Pharmaceuticals Company Profile and Recent Development

      • 14.6.2 Alnylam Pharmaceuticals Market Performance

      • 14.6.3 Alnylam Pharmaceuticals Product and Service Introduction

    • 14.7 RXi Pharmaceuticals

      • 14.7.1 RXi Pharmaceuticals Company Profile and Recent Development

      • 14.7.2 RXi Pharmaceuticals Market Performance

      • 14.7.3 RXi Pharmaceuticals Product and Service Introduction

    • 14.8 Arrowhead

      • 14.8.1 Arrowhead Company Profile and Recent Development

      • 14.8.2 Arrowhead Market Performance

      • 14.8.3 Arrowhead Product and Service Introduction

    • 14.9 Gradalis

      • 14.9.1 Gradalis Company Profile and Recent Development

      • 14.9.2 Gradalis Market Performance

      • 14.9.3 Gradalis Product and Service Introduction

     

    The List of Tables and Figures (Totals 106 Figures and 174 Tables)

    • Figure Japan RNAi for Therapeutic Market Size and Growth Rate of siRNA from 2014 to 2026

    • Figure Japan RNAi for Therapeutic Market Size and Growth Rate of miRNA from 2014 to 2026

    • Figure Japan RNAi for Therapeutic Market Size and Growth Rate of shRNA from 2014 to 2026

    • Figure Market Share by Type in 2014

    • Figure Market Share by Type in 2018

    • Figure Market Share by Type in 2026

    • Figure Market Size and Growth Rate of Cancer

    • Figure Market Size and Growth Rate of Cardiovascular

    • Figure Market Size and Growth Rate of HBV

    • Figure Market Size and Growth Rate of Others

    • Figure Market Share by End-User in 2014

    • Figure Market Share by End-User in 2018

    • Figure Market Share by End-User in 2026

    • Figure Hokkaido RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Tohoku RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kanto RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chubu RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kinki RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Chugoku RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Shikoku RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Kyushu RNAi for Therapeutic Consumption Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of RNAi for Therapeutic Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2018

    • Figure Market Share of TOP 5 Players in 2018

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of RNAi for Therapeutic

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of RNAi for Therapeutic by Different Types from 2014 to 2026

    • Table Consumption Share of RNAi for Therapeutic by Different Types from 2014 to 2026

    • Figure Japan RNAi for Therapeutic Market Size and Growth Rate of siRNA from 2014 to 2026

    • Figure Japan RNAi for Therapeutic Market Size and Growth Rate of miRNA from 2014 to 2026

    • Figure Japan RNAi for Therapeutic Market Size and Growth Rate of shRNA from 2014 to 2026

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of RNAi for Therapeutic by Different End-Users from 2014 to 2026

    • Table Consumption Share of RNAi for Therapeutic by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Cancer

    • Figure Market Size and Growth Rate of Cardiovascular

    • Figure Market Size and Growth Rate of HBV

    • Figure Market Size and Growth Rate of Others

    • Table Japan RNAi for Therapeutic Production by Regions

    • Table Japan RNAi for Therapeutic Production Share by Regions

    • Figure Japan RNAi for Therapeutic Production Share by Regions in 2014

    • Figure Japan RNAi for Therapeutic Production Share by Regions in 2018

    • Figure Japan RNAi for Therapeutic Production Share by Regions in 2026

    • Table Japan RNAi for Therapeutic Consumption by Regions

    • Table Japan RNAi for Therapeutic Consumption Share by Regions

    • Figure Japan RNAi for Therapeutic Consumption Share by Regions in 2014

    • Figure Japan RNAi for Therapeutic Consumption Share by Regions in 2018

    • Figure Japan RNAi for Therapeutic Consumption Share by Regions in 2026

    • Table Hokkaido RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Hokkaido RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Figure Hokkaido RNAi for Therapeutic Consumption Share by Types in 2014

    • Figure Hokkaido RNAi for Therapeutic Consumption Share by Types in 2018

    • Figure Hokkaido RNAi for Therapeutic Consumption Share by Types in 2026

    • Table Hokkaido RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Hokkaido RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Figure Hokkaido RNAi for Therapeutic Consumption Share by End-Users in 2014

    • Figure Hokkaido RNAi for Therapeutic Consumption Share by End-Users in 2018

    • Figure Hokkaido RNAi for Therapeutic Consumption Share by End-Users in 2026

    • Table Tohoku RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Tohoku RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Figure Tohoku RNAi for Therapeutic Consumption Share by Types in 2014

    • Figure Tohoku RNAi for Therapeutic Consumption Share by Types in 2018

    • Figure Tohoku RNAi for Therapeutic Consumption Share by Types in 2026

    • Table Tohoku RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Tohoku RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Figure Tohoku RNAi for Therapeutic Consumption Share by End-Users in 2014

    • Figure Tohoku RNAi for Therapeutic Consumption Share by End-Users in 2018

    • Figure Tohoku RNAi for Therapeutic Consumption Share by End-Users in 2026

    • Table Kanto RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Kanto RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Figure Kanto RNAi for Therapeutic Consumption Share by Types in 2014

    • Figure Kanto RNAi for Therapeutic Consumption Share by Types in 2018

    • Figure Kanto RNAi for Therapeutic Consumption Share by Types in 2026

    • Table Kanto RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Kanto RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Figure Kanto RNAi for Therapeutic Consumption Share by End-Users in 2014

    • Figure Kanto RNAi for Therapeutic Consumption Share by End-Users in 2018

    • Figure Kanto RNAi for Therapeutic Consumption Share by End-Users in 2026

    • Table Chubu RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Chubu RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Figure Chubu RNAi for Therapeutic Consumption Share by Types in 2014

    • Figure Chubu RNAi for Therapeutic Consumption Share by Types in 2018

    • Figure Chubu RNAi for Therapeutic Consumption Share by Types in 2026

    • Table Chubu RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Chubu RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Figure Chubu RNAi for Therapeutic Consumption Share by End-Users in 2014

    • Figure Chubu RNAi for Therapeutic Consumption Share by End-Users in 2018

    • Figure Chubu RNAi for Therapeutic Consumption Share by End-Users in 2026

    • Table Kinki RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Kinki RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Figure Kinki RNAi for Therapeutic Consumption Share by Types in 2014

    • Figure Kinki RNAi for Therapeutic Consumption Share by Types in 2018

    • Figure Kinki RNAi for Therapeutic Consumption Share by Types in 2026

    • Table Kinki RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Kinki RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Figure Kinki RNAi for Therapeutic Consumption Share by End-Users in 2014

    • Figure Kinki RNAi for Therapeutic Consumption Share by End-Users in 2018

    • Figure Kinki RNAi for Therapeutic Consumption Share by End-Users in 2026

    • Table Chugoku RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Chugoku RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Figure Chugoku RNAi for Therapeutic Consumption Share by Types in 2014

    • Figure Chugoku RNAi for Therapeutic Consumption Share by Types in 2018

    • Figure Chugoku RNAi for Therapeutic Consumption Share by Types in 2026

    • Table Chugoku RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Chugoku RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Figure Chugoku RNAi for Therapeutic Consumption Share by End-Users in 2014

    • Figure Chugoku RNAi for Therapeutic Consumption Share by End-Users in 2018

    • Figure Chugoku RNAi for Therapeutic Consumption Share by End-Users in 2026

    • Table Shikoku RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Shikoku RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Figure Shikoku RNAi for Therapeutic Consumption Share by Types in 2014

    • Figure Shikoku RNAi for Therapeutic Consumption Share by Types in 2018

    • Figure Shikoku RNAi for Therapeutic Consumption Share by Types in 2026

    • Table Shikoku RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Shikoku RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Figure Shikoku RNAi for Therapeutic Consumption Share by End-Users in 2014

    • Figure Shikoku RNAi for Therapeutic Consumption Share by End-Users in 2018

    • Figure Shikoku RNAi for Therapeutic Consumption Share by End-Users in 2026

    • Table Kyushu RNAi for Therapeutic Consumption by Types from 2014 to 2026

    • Table Kyushu RNAi for Therapeutic Consumption Share by Types from 2014 to 2026

    • Figure Kyushu RNAi for Therapeutic Consumption Share by Types in 2014

    • Figure Kyushu RNAi for Therapeutic Consumption Share by Types in 2018

    • Figure Kyushu RNAi for Therapeutic Consumption Share by Types in 2026

    • Table Kyushu RNAi for Therapeutic Consumption by End-Users from 2014 to 2026

    • Table Kyushu RNAi for Therapeutic Consumption Share by End-Users from 2014 to 2026

    • Figure Kyushu RNAi for Therapeutic Consumption Share by End-Users in 2014

    • Figure Kyushu RNAi for Therapeutic Consumption Share by End-Users in 2018

    • Figure Kyushu RNAi for Therapeutic Consumption Share by End-Users in 2026

    • Table Company Profile and Development Status of miRagen Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of miRagen Therapeutics

    • Figure Sales and Growth Rate Analysis of miRagen Therapeutics

    • Figure Revenue and Market Share Analysis of miRagen Therapeutics

    • Table Product and Service Introduction of miRagen Therapeutics

    • Table Company Profile and Development Status of Sirnaomics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sirnaomics

    • Figure Sales and Growth Rate Analysis of Sirnaomics

    • Figure Revenue and Market Share Analysis of Sirnaomics

    • Table Product and Service Introduction of Sirnaomics

    • Table Company Profile and Development Status of Quark Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Quark Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Quark Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Quark Pharmaceuticals

    • Table Product and Service Introduction of Quark Pharmaceuticals

    • Table Company Profile and Development Status of Mirna Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Mirna Therapeutics

    • Figure Sales and Growth Rate Analysis of Mirna Therapeutics

    • Figure Revenue and Market Share Analysis of Mirna Therapeutics

    • Table Product and Service Introduction of Mirna Therapeutics

    • Table Company Profile and Development Status of Dicerna Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dicerna Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Dicerna Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Dicerna Pharmaceuticals

    • Table Product and Service Introduction of Dicerna Pharmaceuticals

    • Table Company Profile and Development Status of Alnylam Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Alnylam Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Alnylam Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Alnylam Pharmaceuticals

    • Table Product and Service Introduction of Alnylam Pharmaceuticals

    • Table Company Profile and Development Status of RXi Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of RXi Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of RXi Pharmaceuticals

    • Figure Revenue and Market Share Analysis of RXi Pharmaceuticals

    • Table Product and Service Introduction of RXi Pharmaceuticals

    • Table Company Profile and Development Status of Arrowhead

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Arrowhead

    • Figure Sales and Growth Rate Analysis of Arrowhead

    • Figure Revenue and Market Share Analysis of Arrowhead

    • Table Product and Service Introduction of Arrowhead

    • Table Company Profile and Development Status of Gradalis

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Gradalis

    • Figure Sales and Growth Rate Analysis of Gradalis

    • Figure Revenue and Market Share Analysis of Gradalis

    • Table Product and Service Introduction of Gradalis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US